Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients-Reference-Cited by-同舟云学术

Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients

Published:2017-06-08 Issue:1 Volume:80 Page:209-215
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Kim Bum Jun,Hyung Jaewon,Yoo Changhoon,Kim Kyu-pyo,Park Seong-Joon,Lee Sang Soo,Park Do Hyun,Song Tae Jun,Seo Dong Wan,Lee Sung Koo,Kim Myung-Hwan,Park Jin-hong,Cho Hyungwoo,Ryoo Baek-Yeol,Chang Heung-Moon

Funder

National Research Foundation of Korea

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/article/10.1007/s00280-017-3353-2/fulltext.html

Reference17 articles.

1. Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30

2. Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471–1474

3. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J (2010) ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273–1281